Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2570)	10/28/2010 7:22:39 AM
From: rkrw	2 Recommendations Read Replies (1) \| Respond to of 3027

How do we know this to be true?

To: tuck who wrote (2570)	10/28/2010 7:44:53 AM
From: tom pope	Respond to of 3027

That Teva would continue to assert that it had met all the FDA conditions for full characterization with this POS is astounding. Dew wrote: As presented in #msg-55885444 and #msg-55952595, Lupenox is demonstrably different from Lovenox. The two drugs do not even have the same average molecular weight in their mixtures, which would seem to rule out the possibility that Teva’s product could satisfy the FDA requirements for sameness set forth in #msg-52582225 and in the FDA’s response to Sanofi’s Citizen Petition